ImmuPharma Past Earnings Performance

Past criteria checks 0/6

ImmuPharma has been growing earnings at an average annual rate of 16.7%, while the Pharmaceuticals industry saw earnings declining at 5.2% annually. Revenues have been declining at an average rate of 29.9% per year.

Key information

16.7%

Earnings growth rate

33.4%

EPS growth rate

Pharmaceuticals Industry Growth14.1%
Revenue growth rate-29.9%
Return on equity-91.5%
Net Margin3,519.6%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Shareholders May Be A Bit More Conservative With ImmuPharma plc's (LON:IMM) CEO Compensation For Now

Jun 22
Shareholders May Be A Bit More Conservative With ImmuPharma plc's (LON:IMM) CEO Compensation For Now

How Much Is ImmuPharma's (LON:IMM) CEO Getting Paid?

Dec 02
How Much Is ImmuPharma's (LON:IMM) CEO Getting Paid?

Revenue & Expenses Breakdown

How ImmuPharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

AIM:IMM Revenue, expenses and earnings (GBP Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-212
31 Mar 240-312
31 Dec 230-312
30 Sep 230-312
30 Jun 230-312
31 Mar 230-312
31 Dec 220-412
30 Sep 220-513
30 Jun 220-614
31 Mar 220-714
31 Dec 210-824
30 Sep 210-823
30 Jun 210-833
31 Mar 210-732
31 Dec 200-732
30 Sep 200-642
30 Jun 200-542
31 Mar 200-642
31 Dec 190-643
30 Sep 190-743
30 Jun 190-744
31 Mar 190-744
31 Dec 180-735
30 Sep 180-735
30 Jun 180-735
31 Mar 180-735
31 Dec 170-625
30 Sep 170-525
30 Jun 170-525
31 Mar 170-525
31 Dec 160-515
30 Sep 160-625
30 Jun 160-625
31 Mar 160-524
31 Dec 150-423
30 Sep 150-313
30 Jun 150-312
31 Mar 150-312
31 Dec 140-312
30 Sep 140-322
30 Jun 140-422
31 Mar 140-422

Quality Earnings: IMM is currently unprofitable.

Growing Profit Margin: IMM is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: IMM is unprofitable, but has reduced losses over the past 5 years at a rate of 16.7% per year.

Accelerating Growth: Unable to compare IMM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IMM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9.5%).


Return on Equity

High ROE: IMM has a negative Return on Equity (-91.49%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 12:32
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ImmuPharma plc is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alexander PyeCavendish
null nullCavendish
Navid MalikCavendish Historical (Cenkos Securities)